These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 17699422)

  • 1. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.
    Yerram P; Saab G; Karuparthi PR; Hayden MR; Khanna R
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):258-63. PubMed ID: 17699422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate.
    Kadiyala D; Roer DA; Perazella MA
    Am J Kidney Dis; 2009 Jan; 53(1):133-7. PubMed ID: 19022548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.
    Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C
    Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis.
    Marckmann P; Nielsen AH; Sloth JJ
    Nephrol Dial Transplant; 2008 Oct; 23(10):3280-2. PubMed ID: 18436563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis.
    Richmond H; Zwerner J; Kim Y; Fiorentino D
    Arch Dermatol; 2007 Aug; 143(8):1025-30. PubMed ID: 17709661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA; Rodby RA
    Semin Dial; 2007; 20(3):179-85. PubMed ID: 17555477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL; Thakral C; Skov L; Rossen K; Marckmann P
    Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
    Khurram M; Skov L; Rossen K; Thomsen HS; Marckmann P
    Scand J Urol Nephrol; 2007; 41(6):565-6. PubMed ID: 17934986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report.
    Wiedemeyer K; Kutzner H; Abraham JL; Thakral C; Carlson JA; Tran TA; Hausser I; Hartschuh W
    Am J Dermatopathol; 2009 Oct; 31(7):674-81. PubMed ID: 19633532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.